{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:01:25Z","timestamp":1785351685213,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>L-CHOP (L-asparaginase, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for lymphoma in dogs, but relapse and limited long-term survival are common. Given the radiosensitivity of lymphoma, sequential half-body radiotherapy (HBRT) has been investigated to improve outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Evaluate progression-free survival (PFS), overall survival (OS), and adverse events in dogs treated with a no-maintenance L-CHOP protocol combined with low-dose-rate (LDR, 6\u00a0Gy; 8-14\u00a0cGy\/min) HBRT compared to L-CHOP alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Client-owned dogs with intermediate- to high-grade multicentric lymphoma treated with L-CHOP-LDR-HBRT or a 6-month\u00a0L-CHOP protocol (controls).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records were retrospectively reviewed in this case\u2013control study. Adverse events were graded using VCOG-CTCAE v2 (Veterinary Cooperative Oncology Group\u2014Common Terminology Criteria for Adverse Events guidelines) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-five dogs received L-CHOP-LDR-HBRT and were compared with 115 controls. Median PFS and OS for the L-CHOP-LDR-HBRT group were 532\u00a0days (95% confidence interval [CI], 389-782) and 752\u00a0days (95% CI, 526-963), significantly longer than in controls (296\u00a0days [95% CI, 260-331] and 457\u00a0days [95% CI, 382-553], respectively, P\u00a0&amp;lt;\u00a0.0001). A delay in irradiating the caudal half negatively affected PFS and OS. Adverse event data were available for 30 dogs treated with L-CHOP-LDR-HBRT; most were low-grade, with grade 3 and 4 toxicities occurring in 4.5% of all administered treatments. One dog required hospitalization after HBRT. Dose reductions and treatment delays were observed in 39 and 74 instances, respectively, over the 28-week protocol in this cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Combining L-CHOP with LDR-HBRT, without maintenance chemotherapy, might substantially extend PFS and OS over L-CHOP alone in dogs with multicentric lymphoma, with predominantly mild, manageable toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag144","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:51:28Z","timestamp":1785351088000},"source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes of dogs with multicentric lymphoma treated with sequential half-body radiotherapy and L-CHOP without maintenance chemotherapy"],"prefix":"10.1093","volume":"40","author":[{"given":"Julia","family":"Colosi","sequence":"first","affiliation":[{"name":"Cerro Alto Veterinary Specialty and Emergency Hospital , Oncology Service, San Luis Obispo, CA ,","place":["United States"]},{"name":"William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis , Davis, CA ,","place":["United States"]},{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-7720","authenticated-orcid":false,"given":"Michael S","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C","family":"Close","sequence":"additional","affiliation":[{"name":"EmpiriStat , PO Box 1604, Kitty Hawk, NC 27949 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-1909","authenticated-orcid":false,"given":"Jessica","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-445X","authenticated-orcid":false,"given":"Katherine A","family":"Skorupski","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-3494","authenticated-orcid":false,"given":"Robert B","family":"Rebhun","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rosseel","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Al-Nadaf","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8136-9210","authenticated-orcid":false,"given":"Amandine T","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, Weill School of Veterinary Medicine, University of California, Davis , Davis, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2026072914512104800_ref1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/vco.12163","article-title":"Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"Curran","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2460\/javma.238.4.501","article-title":"Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007)","volume":"238","author":"Flory","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"2026072914512104800_ref4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1476-5829.2012.00324.x","article-title":"Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma","volume":"11","author":"Burton","year":"2013","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1939-1676.2006.tb01810.x","article-title":"Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol","volume":"20","author":"Simon","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1476-5829.2010.00222.x","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"Sorenmo","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/vco.12465","article-title":"A comparison of 12- and 19-week CHOP protocols using non-randomized, contemporaneous controls","volume":"17","author":"Vos","year":"2019","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1476-5829.2011.00311.x","article-title":"Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma","volume":"11","author":"Elliott","year":"2013","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref9","doi-asserted-by":"publisher","first-page":"100461","DOI":"10.1016\/j.tcam.2020.100461","article-title":"Outcome of canine multicentric lymphoma after single or divided treatment with cyclophosphamide in multidrug chemotherapy","volume":"41","author":"Lee","year":"2020","journal-title":"Top Companion Anim Med"},{"key":"2026072914512104800_ref10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2460\/javma.1997.210.04.512","article-title":"Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995)","volume":"210","author":"Valerius","year":"1997","journal-title":"J Am Vet Med Assoc"},{"key":"2026072914512104800_ref12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1939-1676.2000.tb02224.x","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"Chun","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/vr.104077","article-title":"Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma","volume":"180","author":"Lautscham","year":"2017","journal-title":"Vet Rec"},{"key":"2026072914512104800_ref14","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/jvim.17222","article-title":"Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: a European multicenter retrospective cohort study","volume":"38","author":"Hawkes","year":"2024","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/j.1939-1676.2007.tb01959.x","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"Hosoya","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/j.1939-1676.2009.0353.x","article-title":"Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma","volume":"23","author":"Lurie","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1476-5810.2004.00046.x","article-title":"A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma","volume":"2","author":"Gustafson","year":"2004","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1939-1676.2004.tb02609.x","article-title":"Chemotherapy followed by half-body radiation therapy for canine lymphoma","volume":"18","author":"Williams","year":"2004","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1939-1676.1989.tb03087.x","article-title":"Half-body radiotherapy in the treatment of canine lymphoma","volume":"3","author":"Laing","year":"1989","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/vco.13050","article-title":"Half-body radiation therapy results in a prolonged progression-free interval in canine high-grade lymphoma after first remission","volume":"23","author":"Lai","year":"2025","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref21","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/jvim.16840","article-title":"Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation","volume":"37","author":"Best","year":"2023","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1476-5829.2008.00164.x","article-title":"A toxicity study of low-dose rate half-body irradiation and chemotherapy in dogs with lymphoma","volume":"6","author":"Lurie","year":"2008","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12677","article-title":"Veterinary Cooperative Oncology Group\u2014common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"Ak","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/vco.12668","article-title":"Peripheral blood cell ratios as prognostic factors in canine diffuse large B-cell lymphoma treated with CHOP protocol","volume":"19","author":"Henriques","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref25","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1111\/vco.12364","article-title":"Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma","volume":"16","author":"Childress","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1476-5829.2007.00128.x","article-title":"Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma","volume":"5","author":"Turek","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tvjl.2013.05.003","article-title":"Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: prognostic significance and proposal of a cut-off value","volume":"197","author":"Marconato","year":"2013","journal-title":"Vet J"},{"key":"2026072914512104800_ref28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/vco.12661","article-title":"Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma","volume":"19","author":"\u0160kor","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/vco.12263","article-title":"BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy","volume":"15","author":"Curran","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/vco.12184","article-title":"Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma","volume":"15","author":"Poggi","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/vco.12553","article-title":"Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with na\u00efve B-cell lymphoma treated with a 19-week CHOP protocol","volume":"18","author":"Wolf-Ringwall","year":"2020","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/vco.12378","article-title":"Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom","volume":"16","author":"Davies","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1177\/0300985813478210","article-title":"Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival","volume":"50","author":"Valli","year":"2013","journal-title":"Vet Pathol"},{"key":"2026072914512104800_ref34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/vco.12693","article-title":"Response-based modification of CHOP chemotherapy for canine B-cell lymphoma","volume":"19","author":"Benjamin","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026072914512104800_ref35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tvjl.2003.10.009","article-title":"Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy","volume":"167","author":"Ponce","year":"2004","journal-title":"Vet J"},{"key":"2026072914512104800_ref36","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-19-0960","article-title":"Microbiota- and radiotherapy-induced gastrointestinal side-effects (MARS) study: a large pilot study of the microbiome in acute and late-radiation enteropathy","volume":"25","author":"Reis Ferreira","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026072914512104800_ref37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026072914512104800_ref38","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1939-1676.2007.tb01956.x","article-title":"Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol","volume":"21","author":"Vaughan","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026072914512104800_ref39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/4\/aalag144\/70367601\/aalag144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/4\/aalag144\/70367601\/aalag144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:51:29Z","timestamp":1785351089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag144\/8747059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag144","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"aalag144"}}